Carbetocin
Aliases: Duratocin · Pabal
Last verified: 2026-09-23
The short version
A long-acting oxytocin analogue — prevention of postpartum hemorrhage after cesarean section.
Identity & type
- Molecular type
- analog
- Origin
- A long-acting oxytocin analogue — prevention of postpartum hemorrhage after cesarean section.
Mechanism of action
Oxytocin receptor agonism, half-life ~40 min (vs 4–10 min).
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. 100 mcg IV/IM once.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
100 mcg IV/IM once. An obstetric drug: reliably prevents postpartum hemorrhage; not used outside that context.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
An obstetric drug: reliably prevents postpartum hemorrhage; not used outside that context.
Protocol — official vs community
Official / label
Pabal/Duratocin (prevention of uterine atony after cesarean section): 100 mcg (1 mL) as a single IV slow bolus over 1 minute, or IM.
Duration: Single dose at delivery. Repeat dosing is not part of the label; if bleeding continues, additional uterotonics and escalation follow obstetric protocols.
A long-acting oxytocin analogue (elimination half-life ~40 min vs ~10 min for oxytocin) — one dose covers the atony window. Not approved in the US; used widely elsewhere.
Community (anecdotal)
Structured protocol data for this entry is coming.
Human evidence
Approved in 90+ countries.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Similar to oxytocin, mild.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Real-world data outside controlled trials